Tuesday, 04 May 2010 09:05
PositiveID Corporation (Nasdaq: PSID) is developing the non-invasive Easy Check breath glucose analysis system and sources are telling BioMedReports that a bigger company or two have taken an interest in partnering with them for a piece of the huge diabetic market that the test would open up.
As reported earlier, this unique, non-invasive glucose detection system measures the levels of acetone in a patient’s exhaled breath.
It combines a proprietary chemical mixture with exhaled breath, which creates a new molecular compound that can be measured with the Company’s patent-pending technology.
Industry sources say a significant partnership may be very close to completion and public announcement. Such news would not only help validate the technology, but would also likely send PSID's tightly floated shares upward.
In the U.S. alone, 23.6 million people (7.8% of the total population) have diabetes. The PSID device could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading.
Disclosure: Long PSID
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites